Ticagrelor Tablet, Film Coated
Product Images NDC 76282-584

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 76282-584). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Exelan Pharmaceuticals, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A cumulative percentage line graph comparing TICAGRELOR 90 mg with Clopidogrel over 360 days from the first study drug dose. The y-axis shows cumulative % events, and the x-axis shows time in days. The graph includes patient numbers at risk at various intervals and a legend summarizing patient counts and event percentages for each drug group.*
FDA Label Image

Figure 10 (Figure 10)

Figure 10 (Figure 10)
A line graph comparing cumulative event percentages over 360 days for Ticagrelor 90 mg and Clopidogrel, showing event progression from randomization with supporting statistics including number of patients, hazard ratio, and p-value.*
FDA Label Image

Figure 11 (Figure 11)

Figure 11 (Figure 11)
A forest plot chart visualizing the overall treatment effect and subgroup analyses comparing Ticagrelor versus Clopidogrel. It presents hazard ratios (HR) with 95% confidence intervals (CI), including subgroups by geographic region, ASA dose, treatment approach, patient history, age, sex, and race. Data points are shown with horizontal lines representing the CI, and a vertical line at HR=1 for reference.*
FDA Label Image

Figure 12 (Figure 12)

Figure 12 (Figure 12)
A forest plot comparing hazard ratios (HR) with 95% confidence intervals for Ticagrelor versus Clopidogrel by ASA dose ranges and regions (US and Non-US). The plot shows numerical and graphical data for sample sizes and event counts for both drugs, with a horizontal axis indicating relative effectiveness between Ticagrelor and Clopidogrel.*
FDA Label Image

Figure 13 (Figure 13)

Figure 13 (Figure 13)
This chart depicts a cumulative percentage graph comparing the effects of Ticagrelor 90 mg, Ticagrelor 60 mg, and placebo over days from randomization. It includes patient event numbers, Kaplan-Meier percentages at 36 months, hazard ratios with 95% confidence intervals, and p-values for each group. The graph shows cumulative event percentages over time, with a table of patients at risk at various time points below the graph.*
FDA Label Image

Figure 14 (Figure 14)

Figure 14 (Figure 14)
A forest plot illustrating the overall treatment effect and subgroup analyses comparing Ticagrelor versus placebo. The horizontal axis measures hazard ratios from 0.5 to 2.0, indicating Ticagrelor or placebo superiority. Various demographic, clinical characteristics, and treatment timing subgroups are displayed along the vertical axis with corresponding hazard ratios (dots) and 95% confidence intervals (lines).*
FDA Label Image

Figure 15 (Figure 15)

Figure 15 (Figure 15)
A line graph showing cumulative percentage over months from randomization comparing Ticagrelor and placebo groups. The x-axis represents months from 0 to 54, and the y-axis shows cumulative percentage from 0 to 14%. Two lines indicate event rates, with Ticagrelor displayed as a solid line and placebo as a dashed line, showing slightly higher cumulative percentages in the placebo group over time.*
FDA Label Image

Figure 16 (Figure 16.jpg)

Figure 16 (Figure 16.jpg)
A forest plot comparing hazard ratios (HR) with 95% confidence intervals for various patient characteristics in a clinical analysis of Ticagrelor versus placebo. The chart displays subgroups by age, sex, race, BMI, geography, aspirin dose, HbA1c, eGFR, insulin use, angina history, multivessel coronary artery disease, PCI history, time since PCI, CABG history, current smoking, and diabetes duration, presenting event rates and HRs for each.*
FDA Label Image

Figure 17 (Figure 17)

Figure 17 (Figure 17)
A cumulative percentage plot comparing ticagrelor 90 mg twice daily (solid line) versus placebo (dashed line) over approximately 34 days from randomization. The graph shows the number of patients at risk over time and the cumulative events percentage, highlighting differences between the two groups in a clinical study context.*
FDA Label Image

Figure 18 (Figure 18.jpg)

Figure 18 (Figure 18.jpg)
A forest plot chart displaying hazard ratios (HR) with 95% confidence intervals (CI) comparing Ticagrelor versus Placebo across various patient characteristics and subgroups such as age, sex, race, weight, BMI, geographic region, diagnosis, prior conditions, treatment status, and smoking status. The chart visually represents the efficacy outcomes for each subgroup.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A bar chart displaying the percentage of patients who had an event following CABG over several days. The x-axis represents days post-CABG (1 through >=8) and the y-axis shows the percentage of patients (0-100%). Two groups, labeled T and C, are compared for each day with corresponding percentages and patient counts provided below the x-axis.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph showing cumulative percentage over months from randomization, comparing Ticagrelor and placebo groups. The solid line represents Ticagrelor with higher cumulative percentage events than the dashed line for placebo. The x-axis is labeled from 0 to 54 months, and the y-axis shows cumulative percentage from 0% to 7%. A table below the graph lists the number of subjects at risk for each time point for both groups.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A cumulative percentage curve graph comparing ticagrelor 90 mg twice daily versus placebo over days from randomization. The graph shows cumulative event percentages with ticagrelor represented by a solid line and placebo by a dashed line, including numerical data for events and patients at risk over time.*
FDA Label Image

Figure 5 (Figure 5)

Figure 5 (Figure 5)
A line graph showing the percentage of IPA induced by 20 μM ADP over time (hours) for three treatments: Ticagrelor 180 mg, Clopidogrel 600 mg, and Placebo. Ticagrelor shows the highest and rapid increase in IPA, reaching around 90% by 2 hours and maintaining it through 8 hours. Clopidogrel shows a slower, moderate increase to about 50% by 8 hours. Placebo remains near zero IPA throughout.*
FDA Label Image

Figure 6 (Figure 6)

Figure 6 (Figure 6)
A line graph comparing IPA (%) induced by 20 μM ADP over time between ticagrelor, clopidogrel, and placebo across 10 days. Ticagrelor and clopidogrel show higher IPA (%) initially, with ticagrelor peaking earliest, followed by a decline. Placebo remains near zero. An inset graph shows IPA (%) changes over 48 hours.*
FDA Label Image

Figure 7 (Figure 7)

Figure 7 (Figure 7)
A chart showing the mean effect and 90% confidence interval for Ticagrelor and AR-C124910XX across intrinsic factors including age, gender, ethnicity, renal impairment, end stage renal disease on hemodialysis, and mild hepatic impairment. The graph depicts changes relative to reference for pharmacokinetic parameters Cmax (squares) and AUC (triangles) with recommendations of no dose adjustment for all factors.*
FDA Label Image

Figure 8 (Figure 8)

Figure 8 (Figure 8)
A forest plot chart titled 'Mean effect and 90% CI' showing the interaction effects of various drugs with Ticagrelor, comparing pharmacokinetic measures Cmax and AUC between Ticagrelor and AR-C124910XX. The chart presents interacting drugs, effect sizes relative to reference, and recommendations such as avoidance or no dose adjustment for specific drugs including ketoconazole, diltiazem, rifampin, aspirin, desmopressin, heparin, enoxaparin, cyclosporine, morphine, and fentanyl.*
FDA Label Image

Figure 9 (Figure 9)

Figure 9 (Figure 9)
A pharmacokinetic interaction chart showing the effect of various interacting drugs on ticagrelor exposure. The horizontal axis measures change relative to the interacting drug alone. Drug names, ticagrelor doses, and recommendations on dose adjustments are listed. Symbols indicate mean effect and 90% confidence intervals for Cmax and AUC values for each drug interaction.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of ticagrelor, showing its molecular arrangement including fluorinated phenyl ring, triazolopyrimidine core, and sugar moiety.*
FDA Label Image

Ticagrelor Tablets Bottle Of 100 (Ticagrelor Tablets Bottle Of 100.jpg)

Ticagrelor Tablets Bottle Of 100 (Ticagrelor Tablets Bottle Of 100.jpg)
Ticagrelor Tablets 90 mg film-coated oral tablets label by Exelan Pharmaceuticals, Inc. The label shows NDC 76282-550-01 and indicates a package of 100 tablets. It includes storage instructions, dosage guidance, warnings to keep out of children's reach, and manufacturer details including InvaGen Pharmaceuticals and Exelan Pharmaceuticals.*
FDA Label Image

Ticagrelor Tablets Bottle Of 500 (Ticagrelor Tablets Bottle Of 500.jpg)

Ticagrelor Tablets Bottle Of 500 (Ticagrelor Tablets Bottle Of 500.jpg)
Ticagrelor Tablets 90 mg film-coated oral tablets label from Exelan Pharmaceuticals, Inc. The label indicates a package containing 500 tablets. It includes storage instructions, warnings, and manufacturing information, emphasizing pharmacist dispensing of the Medication Guide and child-resistant packaging.*
FDA Label Image

Ticagrelor Tablets Bottle Of 60 (Ticagrelor Tablets Bottle Of 60.jpg)

Ticagrelor Tablets Bottle Of 60 (Ticagrelor Tablets Bottle Of 60.jpg)
Ticagrelor Tablets 90 mg film-coated oral tablets packaging label from Exelan Pharmaceuticals, Inc. The label indicates a quantity of 60 tablets per package and includes storage instructions, a pharmacist dispensing note, and manufacturer details for InvaGen Pharmaceuticals, Inc. and Exelan Pharmaceuticals, Inc. The NDC is 76282-550-60.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.